Carb-X Awards Day Zero Diagnostics $6.2m to Develop a New Test to Diagnose Deadly Superbug Infections Faster and Determine What Antibiotic Would Be Most Effective
Day Zero’s diagnostic is the 60th project funded by CARB-X since 2016.
May 12, 2020 Carb-x.orgAntibiotic Pipeline in Peril from Coronavirus and Incentives System
Kevin Outterson quoted in Axios.
Coronavirus Lessons for the Fight against ‘Superbugs’
Kevin Outterson quoted in Financial Times.
CARB-X Funds Microbiotix
Microbiotix’s new antibiotic targets the trans-translation pathway of the multidrug-resistant bacterium Neisseria gonorrhoeae.
CARB-X Funds Peptilogics
To develop a new class of antibiotics to treat serious superbug infections associated with implants.
New Genomic Tests Aim to Diagnose Deadly Infections Faster
Kevin Outterson quoted in The New York Times.
CARB-X Funds Lytica Therapeutics
The funding will help develop antibacterial peptides to treat drug-resistant infections in the lungs and other parts of the body.
CARB-X Funds Pattern Bioscience
Pattern’s new Digital Culture for rapid ID/AST aims to transform the diagnosis of superbug infections, providing critical information within 4 hours, rather than days.
New Funding to Speed up Taxis Pharma’s Fight against Superbugs
CARB-X featured in NJBiz.
Malvern Drugmaker Is Hopeful Where Others Struggle: Fighting Deadly ‘Superbugs’
CARB-X featured in The Philadelphia Inquirer.